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Abstract

Role of Nucleosome Remodeling Factor (NURF) in Tumorigenesis Using a
Breast Cancer Mouse Model

A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science in Human and Molecular Genetics at Virginia Commonwealth
University
By
Aiman Saud Alhazmi
Virginia Commonwealth University, 2012

Director: Joseph W. Landry, Ph.D.
Assistant Professor
Department of Human and Molecular Genetics

Understanding the impact of epigenetic mechanisms on tumorigenesis is
essential, as epigenetic alterations are associated with tumor initiation and
progression.

Because epigenetic changes are reversible, they are potential

targets for cancer therapy.

Nucleosome Remodeling Factor (NURF) is a

chromatin-remodeling complex that regulates gene expression by changing
nucleosome positioning along the DNA sequence. Previous studies have shown
a role for NURF in embryonic development as well as regulating genes involved
in tumor progression.

In this work we investigated the impact of eliminating

NURF function in tumorigenesis in vivo. BALB/c mice challenged with syngeneic
67NR breast cancer cell lines, injected into the mammary fat pad, lacking NURF,
due to knockdown of its essential subunits Bptf, showed reduction in tumor
XII

growth comparing to control tumors. The observed reduction in tumor growth
was abrogated in immunodeficient mice lacking a functional immune system.
Bptf KD and control 67NR cells grew at similar rates in vitro. Similar findings
were observed in our lab using 66cl4 breast cancer cell lines.

Using

immunofluorescence staining, no significant difference in CD8+, CD4+, NK and
MDSC cells infiltrations into the tumor microenvironment was observed in 66cl4
tumors. Preliminary results from 67NR tumors suggested more CD4+ and CD8+
cells. Gene expression profile of tumor tissues from BALB/c mice injected with
67NR and 66cl4 cell lines showed enrichment of genes associated with immune
response.

Our findings suggested a role of the immune system in targeting

tumor cells lacking Bptf in vivo.

XIII

1- Introduction

1.1- Epigenetics:
During embryonic development cells undergo transitions from the
pluripotent stage to more specialized and lineage committed stages. This
process is achieved by changing gene expression at different stages to ensure
the availability of essential proteins for each cell type (Berdasco & Esteller,
2010). The control of gene expression in the cells is a highly regulated process
that ensures normal growth, differentiation, function and life span of the cell. One
important level of controlling gene expression within the cells is epigenetic
regulation of the genome.
Epigenetics is defined as heritable regulation in a gene expression pattern
that is not due to alteration in the DNA sequence. These regulations modify DNA
or chromatin structure ( Moazed, 2011). Epigenetic regulation of the genome is
important in maintaining the normal gene expression, and account for different
biological mechanisms in eukaryotic cells, including X chromosome inactivation
and genomic imprinting. In addition, many pathological conditions are due to
abnormal alterations in the epigenome including Angelman’s syndrome, PraderWilli Syndrome and different types of cancers (Berdasco & Esteller, 2010)
(Egger, et al., 2004).
As alterations of the epigenetic mechanisms have been found in many
malignant cells, it has been proposed that epigenetic abnormalities are involved
in disease etiology and progression.

Unlike alterations in DNA sequence,
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epigenetic modifications are reversible. Because they are reversed, they are
excellent therapeutic targets. We must understand the role of these mechanisms
in the pathological conditions to design therapeutic approaches that reverse the
abnormal changes (Sharma, et al., 2010).

1.1.1 - Epigenetic Mechanisms:
There are four epigenetic mechanisms involved in regulating gene
expression, and interactions between these mechanisms ensure stable
expression of the genome. These mechanisms are DNA methylation, histone
modification, chromatin remodeling complexes and microRNA (Kim, et al., 2009).

1.1.2- Chromatin Structure:
In eukaryotic cells, genomic material is compacted and localized within the
nucleus in the form of chromatin.

Chromatin is composed of an interaction

between DNA and proteins in which 147 base pairs of DNA is wrapped around
histones H2A, H2B, H3 and H4 (Luger, et al., 1997). This level of compacting
affects exposure of the DNA sequence and can hinder direct interaction with
DNA binding factors such as transcription factors.

1.1.1.2-Chromatin Remodeling Complexes:
The need for chromatin remodeling complexes arises from the fact that
the highly compacted chromatin within the nucleus requires mechanisms to
rearrange nucleosome positions.

This makes DNA element accessible for
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different proteins that promote DNA replication, gene expression, and DNA repair
mechanisms (Wang, et al., 2007). ATP-dependent chromatin-remodeling families
include switching defective/sucrose (SWI/SNF) nonfermenting, imitation switch
(ISWI), chromodomain helicase DNA binding (CHD) and inositol requiring 80
(INO80) function to rearrange nucleosomes positions. These families share an
ATPase domain, and individual complex in each family has different subunits that
account for its functions (Clapier & Cairns, 2009).

1.1.1.2.1-Nucleosome Remodeling Factor NURF:
NURF complex was discovered in D.melanogaster (Tsukiyama & Wu,
1995), and subsequently its homolog has been isolated and found conserved in
H.sapiens indicating the importance of this complex (Barak, et al., 2003). NURF
is a member of ISWI family of chromatin remodeling complexes that share a
conserved ATPase domain (Clapier & Cairns, 2009).

1.1.1.2.1.1- Structure:
Mammalian NURF is composed of three subunits; BPTF (Bromodomain
and PHD-finger Transcription Factor), SNF2L (Sucrose Non-Fermenting 2 Like)
and RBAP46/48 (Barak, et al., 2003) (Figure 1). Studies in Drosophila NURF
(dNURF) found that the Bptf homolog NURF301 and the Snf2l homolog IWSI are
essential for the complex function (Xiao, et al., 2001). BPTF is the largest and
exclusive subunit to mammalian NURF (Barak, et al., 2003). It is a large protein
(~311Kda) that has important domains including; acidic batch, DDT and PHD
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finger domains in the N-terminus, and poly-glutamate repeats, PHD-domain and
bromodomain in the C-terminus. The second essential subunit is SNF2L which
have character features of the ISWI family of chromatin remodeling include the
ATPase domain, HAND, SANT and SLIDE domains (Alkhatib & Landry, 2011).

Figure 1)
a)
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b)

Figure 1: Nucleosome Remodeling Factor NURF's Subunits.
a) The three subunits of the NURF complex. Black is BPTF (Bromodomain and PHDfinger Transcription Factor subunit), Red SNF2L (Sucrose Non-Fermenting 2 Like
subunit) and Blue is pRBAP46/48 (Retinoblastoma-associated Protein 46 and 48). b)
Diagram shows the conserved domains in BPTF subunit between H.sapiens and
M.musculus. Red, Green, Black, Blue and pink represent bromodomain, PHD finger,
polyglutamate repeats, DDT and acidic patch domain respectively. The figure adapted
from (Alkhatib & Landry, 2011).

1.1.1.2.1.2- Function:

The role of NURF as a chromatin remodeler is dependent on a
nucleosome (Tsukiyama & Wu, 1995).

Localization of NURF to its target

sequences can be through; 1- Interaction with transcription factors as is the case
for GAGA factor and progesterone receptor PR that subject NURF to HSP70 and
MMTV promoters respectively (Badenhorst, et al., 2002) (Di Croce, et al., 1999).
2 - Recognition of histone modifications. e.g. binding of the PHD finger in the Bptf
C-terminal with histone 3-lysine 4 trimethyl (H3K4me3) (Wysocka, et al., 2006). 3
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- Presence of a specific DNA binding domain. However, a specific DNA binding
domain for NURF has not been identified yet, its presence is not unexpected
since DNA binding sequence has been identified for Bptf related protein Fetal
Alz-50-reactive clone 1 (FAC1) (Jordan Sciutto, et al., 1999). 4- Recognition of
histone variants. The NURF essential subunit BPTF is localized in nucleosome
with H2A.Z variant (Goldman, et al., 2010). Once recruited, NURF utilizes ATP
to slide the nucleosome position in both directions and expose the DNA
sequence to different regulatory proteins (Hamiche, et al., 1999) (Badenhorst, et
al., 2002).

Many studies have shown that NURF is involved in a number of important
developmental and signaling pathways including TGFβ/Smad, JAK/STAT and
Heat Shock (Badenhorst, et al., 2002) (Landry, et al., 2008) (Kwon, et al., 2008).
In agreement with these findings, eliminating NURF function in a mouse model
by knockout of its largest subunit Bptf is lethal which demonstrates the
requirement of NURF in embryonic development through regulating important
pathways such as Nodal/Smad signaling pathway (Landry, et al., 2008).
Moreover, the same work showed that Bptf knockout in mouse embryonic stem
cells (ESCs) prevents their ability to develop and form teratomas after injection
into NOD/SCID (Non-obese diabetic /Severe combined immunodeficiency).
Collectively, these findings demonstrate the requirement of NURF in cell
development and differentiation in vivo. In addition, gene expression profile from
embryonic stem cells (ESCs), mouse embryonic fibroblasts (MEFs) and double
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positive DP thymocytes identify a number of genes that are involved in different
aspects of carcinogenesis as Bptf dependent genes (Landry, et al., 2008)
(Landry, et al., 2011) these include adherence genes (E-Cadherin, N-Cadherin,
Vimentin and Fibronectin) (Makrilia, et al., 2009) and a group of major
histocompatibility class I (MHC-I) and

class II (MHC-II) genes (Campoli &

Ferrone, 2008). Moreover, in the level of chromatin structure, KD of Bptf leads to
alterations in nucleosome occupancy localized with DNA binding site for CTCF
an important chromatin regulator at important sites such as promoters and
insulators (Millau & Gaudreau, 2011).
Together, these findings suggested that NURF, as an epigenetic
mechanism, might have a role in tumorigenesis.

1.2- Cancer:
Cancer is a term for multiple diseases that share common characteristics
responsible for the associated malignant phenotype.

According to the world

health organization, cancer is the main cause of mortality in the world (Ferlay , et
al., 2010).

Although cancer is a focus of extensive amount of research

worldwide, and much improvement has occurred in terms of detection and
treatment of tumor lesions, the number of new cases and death rates are still
high. In the United States, where cancer is the second cause of death, the
estimated number of new cancer cases in 2012 is around 1.6 million cases, and
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1,500 cancer patients die every day according to 2012 American Cancer
Society’s report (American Cancer Society. , 2012).
Malignant tumors generate from set of cells that undergo uncontrolled
cellular division.

As malignant cells develop, they progressively accumulate

more alterations in the genomic and epigenomic levels that lead to profound
changes in their gene expression profile and growth advantage (Sharma, et al.,
2010). Although malignant tumors can be developed from different tissues and
organs, all tumor types share common capabilities that ensure a tumor’s survival
(Hanahan & Weinnerg, 2011). One of these capabilities is the ability of tumor
cells to escape the effect of the host immune system.

1.2.1- Role of the Immune System in Cancer:
1.2.1.1- The Immune System:
The mammalian immune system is divided into the innate immune system
and the adaptive immune system; both systems are occupied by cellular and
molecular components, and are activated against microbial pathogen, infection
and tumor cells.

The innate immune system’s cellular component includes

macrophages, dendritic cells (DCs), polymorphonuclear granyolocyte (PMNs)
and natural killer cells (NKs), while the adaptive immune system is mainly
composed of T-lymphocyte and B-lymphocytes (Medzhitov, 2007). Both systems
differ in terms of onset of response and the level of specificity against pathogens.
While the innate immune system responds faster and is less specific against
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foreign or non-self antigens, the adaptive immune system has a slower but more
pronounced and specific response.

Cells from both systems are involved in

mediating response against tumor cells. Natural killer cells, as a part of the
innate immune response, and cytotoxic T-cells, as a part of the adaptive immune
response, are the two main cell types that have cytotoxic activity against tumor
cells (Russell & Ley, 2002).

1.2.1.1.1- Natural Killer Cells:
Natural killer cells, as the name depicts, mediate cytotoxic activity upon
activation against target cells (Kiessling, et al., 1975). They have a lymphocytic
origin similar to T- and B-lymphocyte, but they are considered an innate immune
response, as they don’t undergo clonal selection for specific antigens like in Tlymphocyte and B-lymphocyte receptors (Biron , et al., 1987). The cytotoxic
activity of the NK cells can be mediated through secretion of cytotoxic granules
containing perforin and granzyme (Russell & Ley, 2002) or through death
receptors of TNF (Tumor Necrosis Factors) family ligands including TRAIL (TNF
related apoptosis induced ligand) and FasL that are expressed in the surface of
the NK cells (Zamai, et al., 1998). NK cells express two types of cell membrane
receptors; inhibitory receptors include KIR (killer cell immunoglobin-like receptor)
in human, CD94/NKG2A in human and mice, and Ly49 in mice; and activating
receptors e.g. NKG2D and NCR (Natural Killer Receptor). These receptors have
an important role in distinguishing target cells from host cells, and proper
signaling through both receptors ensures the normal function of NK cells
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(Langers, et al., 2012). Ligands for the inhibitory receptors include a set of MHCI molecules that are normally express on surface of nucleated cells and therefore
they inhibit the NK cells from targeting these cells. Down regulation of these
molecules can trigger the NK cells response against these cells as missing selfsignal. Ligands for the activating receptors include Rae-1 and H-60 in mice and
MICA/B in human, which are non-classical MHC-I molecules found to be
overexpressed in malignant cells (Groh, et al., 1999) (Diefenbach, et al., 2001).
Studies have shown that NK cells infiltration into tumor tissues associated with
favorable prognosis in cancer patients (Ishigami, et al., 2000) (Coca, et al.,
1997).

1.2.1.1.2- Cytotoxic T Cells:
Cytotoxic T-cells (CTLs) or CD8+ T-lymphocytes are important cellular
components of the adaptive immune system that are responsible to mediate
cytotoxic activity against infected and tumor cells.

Upon activation, CTLs

mediate killing of target cells through two mechanisms, similar to NK cell, perforin
mediated cytotoxicity and Fas/FasL pathway (Russell & Ley, 2002). CTLs
recognize MHC-I molecules, which are expressed on all nucleated cells.
Malignant cells express tumor-associated antigens (TAAs) that can be presented
in the cell surface by the MHC-I through the antigens presenting machinery APM.
TAAs include peptides of mutated genes or germ line genes that are abnormally
expressed in transformed somatic cells (Restifo, et al., 2012). Infiltration of CTLs
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into tumor tissues is associated with favorable outcomes in cancer patients
(Naito, et al., 1998).
Antigens loading on the MHC-I are a sequential mechanism that starts by
degradation of ubiqutinated proteins in the cytoplasm through immunoproteosom,
which contains Psmb9 and Psmb8 catalytic subunits (Angeles, et al., 2012). The
resulted peptides are transported to the endoplasmic reticulum (ER) through
heterodimer of two transporter proteins TAP1 and TAP2 (ATP-binding cassette-1
and 2).

Inside the ER the peptides loaded into MHC-I molecule, which is

composed of α chain and β2m, in the ER membrane through tapasin (Tapbp)
(Seliger, et al., 2000). The resultant complex, MHC-I and the peptide, is then
transport to the cell membrane.

1.2.1.1.3- T-helper Cells:
The second cellular component of the adaptive immune system is Thelper cells. This set of cells characterized by expressing CD4 co-receptor on the
cell surface and recognizing antigens such as TAAs that are presented on MHCII molecules, which express in the antigen presenting cells APCs (macrophage,
dendritic cells and B-cells) (Pieters, 1997). The T-helper cells further subdivided
into Th-1 and Th-2 based on the cytokines expression (Kidd, 2003). In context of
antitumor response, Th-1 is known to augment the CTLs activity and enhance
the antitumor response through promote APCs activation and secretion cytokines
such as INF-γ (Yu & Fu, 2006), which induce expression of MHC-I molecules in
tumor cells. (Ikeda, et al., 2002). Th-2 has a pro-inflammatory role and studies
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have shown that these cells might promote tumor growth in some type of cancers
(Kidd, 2003).

1.2.1.2- Cancer Immunosurveillance:
Cancer immunosurveillance is defined as the ability of the host immune
system to detect and eliminate tumor cells (Burnet, 1970).

While the main

function of the immune system is protecting the host from foreign cells, the
tumor-associated antigens expressed by a tumor cells are the signals that
distinguish malignant cells from host cells and trigger the immune system
attention to these cells (Smyth, et al., 2001).

The concept of cancer

immunosurveillance is supported by number of findings in mouse models lacking
essential components of the immune response, as well as observations from
cancer patients (Dunn, et al., 2004).

For instance, mice with non-functional

adaptive immune response due to homozygous knockout of the recombinase
activating gene RAG-2, which is important in maturation of functional Tlymphocyte and B-lymphocyte receptors ( Shinkai, et al., 1992), were more
susceptible to develop tumors following treatment with a carcinogen compound
(Methylcholnthrene MCA) compared to wild type mice (Shankaran, et al., 2001).
Also, the innate immune system has been found to play a role in tumor
immunosurveillance.

Mice treated with monoclonal antibodies that inhibit NK

cells developed more MCA-induced tumors comparing to control mice (Smyth, et
al., 2001).

The role of the immune system has been observed in human.

Epidemiological studies have shown a relative increase in cancer incidence rate

12

among immunocompromised patients (Birkeland, et al., 1995). Also, histological
studies have shown localization of the immune cells into tumor tissues, which
indicates an activation and recruitment of these cells into the tumor environment
(Naito, et al., 1998). Isolating CD8+ T-cells as well as antibodies against specific
tumor associated antigens from cancer patients support the role of adaptive
immune system against growing tumors in human (Dunn, et al., 2004).

1.2.1.3- Evasion of the Immune System:
The existence of cancer as a pathological condition in immunocompetent
individuals led to suggest a continuous interaction between tumor cells and
immune system which has two end points; either the immune system
successfully eliminates the tumor cells (immunosurveillance) or the malignant
cells evade the immune system (evasion of the immune response) (Dunn, et al.,
2004).
Findings from tumor injection studies in mice lacking important immune
system components suggest an additional role of the immune system against
tumor cells described as immunoediting (Dunn, et al., 2004).

Work by

Shankaran et al. showed that tumors that grew in RAG2 -/- mice without
functional adaptive immune system failed to form tumors upon re-injection into
wild type mice, but were able to form tumors when they were re-introduced into
mice with suppressed immune system (Shankaran, et al., 2001). On the other
hand, tumors that grew in mice with a functional immune system were able to
form tumors when they re-injected into wild type mice. From these observations,
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it has been suggested that the level of immunogenicity of tumor cells is affected
by the action of immune response against tumor cells, and the immune system
acts as a selective factor that eliminates the highly immunogenic cells (easily
detected by immune system) and allows survival of cells that have low
immunogenic phenotype.

During tumor progression, malignant cells accumulate genetic and
epigenetic alterations that lead to generate a heterogeneous population in the
tumor microenvironment. The antitumor effect of the immune system acts as a
selective agent against the malignant cells (Vesely, et al., 2011).

Cells with

immunogenic phenotype are eliminated while cells that develop resistance
mechanisms can avoid destruction. Eventually, this set of cells progressively
develops and becomes predominant in the tumor site (Birkeland, et al., 1995).
Mechanisms that can be developed by tumor cells to avoid the immune system
include; reducing tumor immunogenicity, reducing the effect of the CTL and NK
cytotoxicity through overexpressing anti-apoptotic molecules or depressing the
death signaling pathways; secretion of cytokines that can either inhibit the
immune cells activity e.g. interleukin 10 (IL-10), tumor growth factor beta (TGF-β)
and vascular endothelial growth factor (VEGF) (Khong & Restifo, 2002) or recruit
and amplify immunosuppressor cells such as myeloid derived suppressor cells
(MDSCs) and regulatory T-cells (Vesely, et al., 2011).
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1.2.1.3.1-Reduce Tumor Cell Immunogenicity:
Down regulation of antigens presenting MHC-I molecules is one way
which tumor cells can avoid cytotoxic T cells (Garrido, et al., 1997), and has been
reported in many tumor types (Algarra, et al., 1997). Down regulation of MHC-I
molecules can be through irreversible genetic alterations that affect MHC-I genes
or through reversible epigenetic silencing. In addition, reduction in tumor cells
immunogenicity can be mediated by silencing the antigens presenting machinery
(APM) genes including Psmb8, Psmb9, TAP-1, TAP2 and tapasin (Seliger,
2008). However, as MHC-I molecules are expressed in all nucleated cells, they
serve as inhibitory ligands for the inhibitory receptors on NK cells.

1.2.1.3.2-Recruitment and Amplification of MDSCs:
Myeloid derived suppressor cells (MDSCs) are a group of heterogeneous
immature myeloid cells. An increase in number of MDSCs has been associated
with tumors in mouse models and cancer patients (Gabrilovich & Nagaraj, 2009).
In

response

to

different

cytokines

that

are

released

within

tumor

microenvironment, which include (granulocyte macrophage colony stimulating
factor (GM-CSF), interleukin-1 beta (IL-1 β), tumor growth factor beta (TGF-β)
and prostaglandins, there is an expansion and activation of the MDSCs
population (Naiditch, et al., 2011). In the tumor microenvironment, MDSCs have
a

negative

effect

on

the

immune

response

through

secretion

of

immunosuppressive factors e.g. arginase and inducible nitric oxide (iNOS) that
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cause depletion of important amino acids for T-cell activation such as arginine
and cysteine (Gabrilovich & Nagaraj, 2009).

1.2.1.3.3-Regulatory T-cells:
Regulatory T-cells are a group of cells that regulate the host immune
response through suppression of CD4 and CD8 cells, and they infiltrate into
tumor microenvironment (Piersma, et al., 2008).

Depletion of these cells

promotes autoimmune response against self-antigens (Yu & Fu, 2006). CD4
regulatory T-cells (CD4+ CD25+ Fox3+ (fork-head box protein3)) are well studied
regulatory T-cells, and they mediate their suppresser activity through cell-cell
interactions, secretion of inhibitory cytokines such as IL-10 and TGF-β or
depleting IL-2 (Schametterer, et al., 2012). Also, studies have shown that CD8
regulatory T-cells infiltrate into tumor tissues and might have similar
immunosuppressive function (Wang, 2008).

1.3- Hypothesis:
Along with mutations, epigenetic alterations are associated with tumor
development and progression. Previous findings indicated that there is a role of
NURF in embryonic development, teratomas formation and regulating important
genes in cancer suggest a role of NURF in tumorigenesis. We hypothesized that
eliminating NURF function might reduce tumor growth in vivo. Toward this end
we proposed the following aims;
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Aim 1- To investigate tumor growth in mice after injection of Bptf KD
67NR breast cancer cells.

Using a syngeneic mouse model, 67NR Bptf

knockdown and control breast cancer cells were injected into mammary fat pad
of BALB/c mice and NOD SCID gamma (NSG) mice. After 3 weeks, the tumors
were surgically removed and tumor weights were measured. Tumors were also
processed in aims 2 and 3.
Aim 2- To measure immune cells infiltration into the tumor site
following Bptf KD. As findings from the previous experiments suggested a role
of the immune system in the observed phenotype, we screened for immune cells
infiltration into tumor sites.

Using immunofluorescence staining, frozen

histological sections were stained with CD8a, CD4, NKp46 and CD11b antibody
for CTL, T-helper, NK and MDSC cells, respectively. These experiments
attempted to determine if reduction in tumor growth are the result of increased
immune cell infiltration
Aim 3- To identify gene expression profile in Bptf KD from tumor
tissues. The findings from aim 1 suggested that Bptf KD promote the antitumor
immune response against the tumor cells.

Tumors from BALB/c mice injected

with Bptf KD and control 67NR and 66cl4 cell lines were subjected for microarray
analysis.
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2- Methods and Materials:

2.1- Mice and Cell Lines:
BALB/c and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ female mice (NOD scid
gamma NSG mice) were provided from the Jackson Laboratory (Bar Harbor,
ME). Mouse breast cancer cell lines (4T1, 66cl4 and 67NR) were obtained from
Dr. Fred R. Miller at Wayne State University (Detroit, MI). Mice were harvested at
the barrier facility in the Molecular Medicine Research Building, Virginia
Commonwealth University (Richmond, VA). Cells were maintained in 1X high
glucose DMEM Dulbecco’s Modified Eagle Medium provided by Invitrogen life
technology (Grand Island, NY). The media contains 1X Non-essential amino
acids, 2 mM L-Glutamine both provided by GIBCO Invitrogen (Grand Island, NY),
10 % fetal bovine serum, 1X penicillin and streptomycin provided by Mediatech
Inc. (Manassas, VA). Cells transfected with Bptf short hairpin was maintained in
media contains 5 µg/ml of Puromycin, as a selective agent, provided by
Invitrogen (Grand Island, NY). Cells were maintained in 6 wells, 12 wells plates
or 10 cm dishes at 37 °C and 5 % CO2 in tissue culture incubator.

2.2- Bptf Stable Knockdown Cell Lines:
In order to generate stable Bptf knockdown (KD) cell lines, the Retro-X™
system (cat. No. 631598) and pSIREN-Retro-Q vector (Cat. No. 631526) were
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used, provided by Clontech (Mountain, CA) to generate retrovirus vector with
short hairpin specific sequence targeting Bptf gene.
Two short hairpins were used (KD-1 and KD-2) to knockdown Bptf; KD-1 (5’CGACGATGACTCCGATTATT-TCAAGAG-AATAATCGGAGTCATCGTCG-3’);
KD-2(5’-GGCGAAAACCAAGAGTACAT-TCAAGAGATGTACTCTTGGTTTCGCC-3’). Non-specific sequence was used as a control
(5’-GTGCGTTGCTAGTACCAACTT-TCAAGAG-3’).

pSIREN-Retro-Q vector

contains shRNA sequence was transfected into PT67 packaging cell line to
generate retrovirus vector. PT67 cells were plated in medium without Puromycin
for 2-3 days to generate the virus. Then, the medium, which contains the virus,
was collected, filtered and added to 67NR breast cancer cells in 6 wells plate for
2-3 days. The medium was then replaced with medium containing Puromycin (5
μg/ ml) for selection of cells that integrated the viral genome.

Each well

represents a single transduction event.

2.3- Cell Counting:
Cells were plated in 10 cm dish with 10 ml of media for 48 hours. The
media was removed and cells were washed with 1 ml of 0.25 % Trypsin and 1
mM EDTA and again incubated in 1 ml of Trypsin + EDTA for 1 to 2 minutes in
the incubator to release the cells from the dish. Next, 3 to 5 ml of media was
added, and cells were counted using the hemocytometer slide or the Cell meter
Auto T4 from Nexcelom Bioscience (Lawrence, MA). 0.2 % Trypan blue provided
from Sigma-Aldrich (St. Louis, MO) was used to count cells for injection.
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2.4- Population Doubling Time:
In 3 plates of 12 wells plate cells were seeded at 1X104 cells/ ml with 2 ml
of media. For each plate 4 wells were used for control and 4 wells for knockdown
cells. Cells were counted at 24 hours, 48 hours and 72 hours as one plate for
each time point. The population doubling time was measured using doubling time
calculator

software

from

Roth

V.

2006

http://www.doubling-

time.com/compute.php.

2.5- Mice Injection and tumors collection:
6 to 8 weeks of age female mice were anesthetized with isoflurane
provided by Clipper distribution company (St. Joseph, MO), and were injected
with 1X105 67NR control shRNA and Bptf shRNA knockdown cells into the
mammary fat pad. Cells were diluted into 2X106 cells/ml, and 50 μl was injected
into the mice. Three weeks post injection; mice were sacrificed using carbon
dioxide. Tumors were surgically removed, and immediately frozen with liquid
nitrogen in 15 ml conical tube. Tumor weight was measured by weighing each
15 ml conical tube before and after a tumor is added. The difference between
the two weights was used as the tumor weight. Tumor samples were stored at 80°C.
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2.6- Western Blotting:
Proteins were extracted from tumor tissues and monolayer cells using TRI
Reagent® (as a lysis reagent) provided by Sigma-Aldrich (St. Louis, MO). Tumor
tissues were chopped and 0.05 - 0.1 g of tissue was homogenized with 1 ml of
TRI reagent using electronic homogenizer. Monolayer cells were washed with 1x
PBS, then 1 ml of TRI was added and incubated for 5 minutes.

Then, the

homogenates were transferred into 1.5 ml tubes, and 200 μl of chloroform was
added and the samples were incubated for 10-15 minutes. Then, samples were
centrifuged for 15 minutes at 20,000 rcf (relative centrifugal force) at 4°C. Three
layers were formed; an aqueous phase contains the RNA, an interphase contains
the DNA and an organic phase contains the proteins were in (bottom layer).
After removing the aqueous and interphase, 1 ml of isopropanol was added and
the tubes were incubated at room temperature for 10 minutes.

Then, the

samples were centrifuged at 20,000 rcf for 15 minutes at 4°C. The supernatants
were discarded and 1 ml of 0.3 M guanidine in 95% ethanol was added for
overnight wash at 4°C on shaker.

Then, the guanidine was removed by

centrifugation and 1 ml 100 % ethanol was added and incubated for overnight at
4°C on shaker. After removing the ethanol, 250 μl of 8 M urea in 1% SDS was
added, and samples were incubated at 65°C overnight. Protein concentration
was measured using Bio-Rad Dc Protein Assay provided by Bio-Rad Laboratories
(Hercules, CA) using BSA standards. The proteins were dissolved in 2 mg/ml
concentration. 50 µg of protein was loaded into 4% gel for SDS-PAGE, and run
for 1 hour at 200 V and 300 mA.

Next, proteins were transferred into
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polyvinylidene fluoride PVDF membrane provided by Bio-Rad Laboratories
(Hercules, CA) for 17 hours at 20 V and 30 mA. After the transfer the membrans
were blocked with 5% non-fat dry milk for 1 hour. Then, Bptf primary antibody
was used at 1:5000 dilution and incubated for overnight at 4°C. Following three
times washing with PBST (phosphate buffer saline with 0.1% Tween 20) for 5
minutes each, the membrans were incubated with ECL peroxidase labeled antirabbit secondary antibody at 1:10,000 dilution for 1 hour. The plots were then
washed for 5-10 minutes with PBST for 3 times and developed using supersignal
West Femto Substrate from Thermo Scientific (Rockford, IL).

2.7- Immunohistochemistry:
Frozen tumor tissues were embedded in O.C.T compound (Optimal
Cutting Temperature) from Sakura Finetek (Torrance, CA). Tissue samples were
sectioned at -20 to -25°C with 5 μm thickness using vibratome ultra pro 5000.
Cryosections were fixed with acetone for 10 minutes, followed by 10 minutes air
dry. Sections were then washed two times with 1 X PBS for 5 minutes each.
Then, sections were blocked for 1 hour using 1% BSA (bovine serum albumin)
was provided by Sigma-Aldrich (St. Louis, MO). Then, primary antibodies were
added at 1:50 dilution for 1 hour. Four rat anti-mouse primary antibodies were
used for CD8, CD4, CD11 and NK cells as follow (CD8a cat. No. 550281), (CD4
cat. no.550280), (NKp46 cat no. 560754) and (CD11b cat. no. 557395) provided
by BD Biosciences (San Jose, CA). Sections were then washed three times with
PBST for 5 minutes and secondary antibody was added. Secondary antibody
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was goat anti-rat IgG-FITC antibody Lot# K1711 provided by Santa Cruz
Biotechnology (Santa cruz, CA). Then, Slides were washed three times with PBS
for 5 minutes each and vectashield® was used as mounting media provided by
Vector Laboratories, Inc (Burlingame, CA).

Sections were examined using

Olympus BX41 Fluorescence microscope under FITC channel.

2.8-RNA Extraction and Quantitative RT-PCR:
Total RNA was extracted using TRI reagent® (as a lysis reagent) provided
by Sigma-Aldrich (St. Louis, MO) from the breast cancer cell lines grown in 10
cm plate. The cells were washed with 1X PBS and 1 ml of TRI reagent was
added and incubated for 5 minutes. Then, the contents were transferred to 1.5
ml centrifuge tubes and 200 μl chloroform was added. Samples were mixed by
vortexing and incubated for 10-15 minutes.
21,000 rcf for 15 min at 4°C.

Tubes were then centrifuged at

The resulted aqueous phase, which contains the

RNA, was transferred into a new 1.5 ml tubes. 100 μl of acidic phenol was
added and samples were centrifuged. RNA precipitation was achieved by adding
250 μl of isopropanol and 250 μl of RNA precipitation solution as ¼ the volume of
the TRI reagent for each compound. RNA precipitation solution composed of
(1.2 M NaCl and 0.3 M disodium citrate).

After mixing the contents and

incubating the tubes for 10 minutes at room temperature, the tubes were
centrifuged at 21,000 rcf for 15 minutes at 4°C.

The resulted pellets were

washed for two times with 70% ethanol and RNA was dissolved in 50 μl
molecular grade water. RNA integrity was investigated by running 1.5% agarose
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gel to check for the presence of two un-smeared rRNA bands. The absorbance
at 260 and 280 wavelengths was measured by NanoDrop® ND-1000
spectrophotometer provided by Thermo scientific (Wilmington, DE).
RNA was converted to cDNA using Superscript™III kit from Invitrogen life
technology (Grand Island, NY). 1 μg of total RNA was used in reaction mixture
that include 10 μl of 2X RT reaction mix, 2 μl reverse transcriptase and volume of
molecular grad water to make the total volume 20 μl. The thermo cycle was as
follow: 25°C for 10 minutes; 50°C for 30 minutes and 85°C for 5 minutes. Then,
1 μl of RNase H was added and tubes incubated for 20 minutes at 37°C.
Quantitative RT-PCR was used to confirm the microarray results. SYBR
green ABsolute SYBR Green ROX Mix from Thermo Scientific (Rockford, IL) was
used. The reaction mixture was prepared as follow: 5 μl of primers 280 nM
(forward and reverse primers), 5 μl of cDNA and 10 μl of SYBR Green ROX Mix.
The qRT-PCR condition was as follow: 95ºC for 15min, then 50 cycles of 95ºC
for 10 seconds, 60ºC for 30 seconds and 72ºC for 30 seconds. Disassociation
curve cycle has been added at the end. Gene expression was calculated using
comparative Ct value. β-actin was used as endogenous gene to normalize the
gene expression in control and knock-down samples.
-Primer Sequences
Primers were designed using www.ncbi.nlm.nih.gov/tools/primer-blast/ , and
provided by eurofins mwg|operon (Huntsville, AL) (Table 1).
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Table 1)
Gene
Symbol
H2-Mb2
Cxcl16
Cxcl9
H2-Dma
β-actin
Lmp7
Tap2
Tapbp
Lmp2
H2-D1
Ccnd1a
Ccnd1b

Primer Sequence
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

5'-TGTGCCACCCACACCCAACCTT-3'
5'-GTCTCCATTGGGCTGAGCCGT-3'
5'-GACCCTGCCAGGCGATGGCAAC-3'
5'-GGCTTCCCCCACACACGCTTT-3'
5'-TCAGCTCTGCCATGAAGTCCGC-3'
5'-ACTAGGGTTCCTCGAACTCCACAC-3'
5'-TCCCAGTGTCCAGAGGTTTGCCTGT-3'
5'-TGCCTAGCACACCGAGGCCA-3'
5'-CCCCATTGAACATGGCATTG-3'
5'-ACGACCAGAGGCATACAGG-3'
5'-TTGGCCAAGGAGTGCAGGTTGTAT-3'
5'-GTCCCGAGAGCCGAGTCCCAT-3'
5'-CGCCTTTGCAAGCGCCATCTTT-3'
5'TCGAGTTCAGCTCCCCTGTCTT-3'
5'CTGGCTGGTAGCTGCCTACTGGACC-3'
5'-TGAGGGTGGCTTCCACAGACGA-3'
5'-CTCTGCTGAGATGCTGCGGGC-3'
5'-CCACTGCTGTTCCCGCTGACAC-3'
5'-GAGCCTCCTCCGTCCACTGACTC-3'
5'-CCAGGCAGCTGTCTTCACGCTTTA-3'
5'-CACAACGCACTTTCTTTCCA-3'
5'-ACCAGCCTCTTCCTCCACTT-3
5'-GATTTGGCACCTCTCAGCTC-3'
5'-TGGTGAACAAGCTCAAGTGG-3'

2.9- Microarray Analyses:
Microarray experiments and analysis were performed in Dr. Catherine I. Dumur’s
Laboratory at Molecular Diagnostic Laboratory.

RNA extraction, microarray

analysis and statistical analysis were performed as described in (Singh, et al.,
2011) (Dumur, et al., 2008).

Tumor tissues subjected to gross histological
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analysis using hematoxylin and eosin stain to determine percentages of tumor
cells, necrotic and stromal cells before tissues were isolated for the RNA
extraction. Most of the tumors have 100 % to 70 % tumor tissues and necrotic
tissues, if present, were selected out by macrodissection. TRIZOL reagent and
MagMAX™-96 for microarray total RNA isolation kit provided from Life
technology Ambion® (Austin, TX) were used to extract total RNA from frozen
tumor tissues in the automated magnatic particle processor MagMAX express
from

Applied

Biosystem.

Then,

using

2100

Bioanalyzer

from

Agilent

Technologies (Foster City, CA) 1 μl of sampes was applied to RNA ND8000 Lab
Chips® to assess the RNA purity and integrity at 260, 270 and 280 nm. Then, 5
μg of total RNA were used for cDNA synthesis and in vitro transcription to
generate biotinylated cRNA using the GeneChip® 3’ IVT express kit provided by
Affymetrix (Santa Clara, CA). Hybridization conditions for the fragmented cRNA
on the GeneChip®Mouse Genome 430A 2.0 Array were 16 hours at 60 rpm
(round per minutes) at 45°C, and 10 μl of fragmented cRNA were used. Then,
using Affymetrix fluidics work station the microarrays were washed and stained
with streptavidin phycoerythrin provided from Molecular probes (Eugene, OR).
The microarrays were then scanned as previously described using the Affymetrix
GeneChip® scanner 3000 and data were saved as .dat and .cel files. The array
quality was accepted if the 3’/5’ ratio of the housekeeping gene (GAPDH) is less
than three and the present gene % is more than 40%.
Microarray Statistical analysis was performed as previously described
(Singh, et al., 2011). Log-scale robust multiarray analysis RMA was used for
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noise correction, normalization and estimation for probe expression. Relative
difference between control and KD samples were analyzed using two-sample-ttest for each pairwise comparison, and to determine differentially expressed
probes at univariat level α-level equal 0.01 was used.

q-value was used to

correct for multiple comparisons in the microarrays experiments, each p-value
was corrected for multiple testing using FDR false discovery rate < 15%.
Gene Ontology analysis was performed using DAVID the Database for
Annotation, Visualization and Integrated Discovery v 6.7
http://david.abcc.ncifcrf.gov/.

Functional annotation chart tool was used to

determine the highest enrichment terms in the probe set lists that have 2 or more
fold changes.

3.10- Statistical Analysis:
Significance difference between control and knockdown samples was
determined using two-tail student t-test.
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3- Results

3.1- Knockdown of NURF Function Reduces Tumor Growth in a Mouse
Model.
NURF is a chromatin-remodeling complex that regulates gene expression
by changing nucleosome position. Work by Landry et al., showed that NURF is
essential during embryonic development, as mouse lacking Bptf, which is an
essential subunit of NURF (Xiao, et al., 2001) is not viable (Landry, et al., 2008).
They also showed that ESCs lacking Bptf were unable to form teratomas in
NOD/SCID mice.

Gene expression profile of Bptf KO ESCs, MEFs and DP

thymocyte revealed a role of Bptf in regulating number of genes involved in
cancer progression including MHC-I genes, N-cadherin and E-cadherin genes
(Landry, et al., 2008) (Landry, et al., 2011). Together these findings led us to
hypothesized that eliminating NURF function might reduce tumor growth in vivo.
To test our hypothesis we chose a BALB/c mouse breast cancer model
developed by Fred Miller. This model has many advantages including (i) it is
very well characterized mouse model (Aslakson & Miller, 1992), (ii) allows to
investigate tumor cells growth in vivo with intact immune system (Ottewell, et al.,
2006), (iii) it resembles human breast cancer metastasis (Lelekakis,, et al., 1999)
and (iv) it is convenient to use as cells can be easily injected into mammary fat
pad and form tumors within 3 to 4 weeks. In this model there are five cell lines
(4T1, 66cl4, 4T07, 168 FARN and 67NR) that were originally derived from a
single spontaneous mammary tumor developed in a BALB/c mouse. These cell
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lines differ in their ability to metastasize; 4T1 cells disseminate through blood and
metastasize to the lung, liver, brain and bone; 66cl4 cells disseminate through
lymph and metastasize to the lung; 168FARN and 4T07 disseminate through
lymph and blood, respectively but fail to metastasize and 67NR cells have the
ability to form primary tumors, but unable to disseminate from the primary site
(Aslakson & Miller, 1992). This work focused on 67NR cell lines. The impact of
NURF in the two metastatic cell lines (4T1 and 66cl4) is a subject of another
work done by Suehyb Alkhatib in our lab.
First, we wanted to confirm the expression of NURF in the selected cell lines.
Work done by S. Alkhatib showed the presence of NURF subunits (Bptf, Snf2L
and pRbAp46/48) in these cell lines (Figure 2).
Figure 2)
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Figure 2: Expression of NURF Subunits in Breast Cancer Cell Lines.
Expression of Bptf, Snf2L and pRbAp46/48 NURF's subunits in 66cl4, 4T1, 4T07,
168FARN and 67NR breast cancer cell lines using Western Blotting. Ponceau stain was
used to confirm equal protein loading.

Next, eliminating functional NURF can be achieved by knockdown of its
essential and exclusive subunit Bptf (Xiao, et al., 2001) (Landry, et al., 2008).
Toward this end we generated stable Bptf KD 67NR cell lines using retrovirus
vector to introduce short hairpin targeting Bptf. We used two shRNAs (named as
knockdown-1 (KD-1) and knockdown-2 (KD-2)) to create two different Bptf KD
cell lines to control for off target effect. A nonspecific RNA sequence was used
as a control (Figure 3).

Figure 3)
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Figure 3: Bptf KD in 67NR Breast Cancer Cell Lines.
Western Blotting is showing Bptf KD using two different shRNAs (KD-1 and KD-2). Nonspecific RNA sequence was used as a control. Ponceau stain was used to confirm
equal protein loading.

Next, In order to investigate roles of NURF in tumor growth we injected
1X105 67NR cells into the mammary fat pad of syngeneic BALB/c mice. Mice
injected with three group of cells; (i) cells transfected with non-specific shRNA as
a control, (ii) cells transfected with KD-1 and (iii) cells transfected with KD-2. The
tumors were collected three weeks after injection. We observed significant (pvalue < 0.005) reduction in tumors weight and tumors formation in both KDs
comparing to the control tumors (Figure 4). While all the mice injected with the
control cells formed tumors except one, only 3 out of 13 and 6 out of 16 of mice
injected with the KD-1 and KD-2 cell lines, respectively, formed tumors.
Knockdown of Bptf in the tumor tissues was maintained comparing to the control
tumors (Figure 5). Similar reduction in tumor growth but not in frequency was
observed with the 66cl4 cell lines (by Suehyb Alkhatib, data not shown). These
findings suggested that eliminating NURF has a negative effect on tumor growth.

31

Figure 4)
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Figure 4: Knockdown of NURF Function Leads to Reduction in Tumor Growth in
vivo.
Tumors weights form mice injected with control, KD-1 and KD-2 67NR breast cancer cell
lines. Significant (p-value < 0.005) reduction was observed in KD-1 and KD-2 tumors
relative to the control tumors. Error bar represent standard deviation of 13 tumors for
each group.
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(Figure 5)

Figure 5: Bptf KD in Tumor Tissues.
Western Blotting is showing Bptf expression level in tumor tissues injected with control,
KD-1 and KD-2 67NR breast cancer cell lines. Non-specific control shRNA sequence
was used as a control. Ponceau stain was used to confirm equal protein loading.

3.2 – 67NR cells Lacking NURF Proliferate Normally in vitro.
The observed reduction in vivo can be due to a role of NURF in cellular
growth, as a result KD of Bptf can lead to reduce the cell growth efficiency in
vitro. To exclude the possibility that the observed reduction in tumor growth was
due to effect on cellular growth, we measured the population doubling time of the
67NR control and Bptf KDs cell lines in vitro (Figure 6). In this experiment, the
required time for an entire population of cells to double their number was
measured. No significant difference was observed between the control cell lines
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and the two KD cell lines. Similar result was observed with 66cl4 breast cancer
cell lines (S. Alkhatib, data not shown). This observation suggested that the
observed reduction in tumor growth (Figure 4) is due to an effect in vivo.
Figure 6)
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Figure 6: Normal Proliferation Rate for 67NR Cells Lacking NURF in vitro.
Population doubling time experiment for control, KD-1 and KD-2 67NR breast cancer cell
lines. 1✕104 cells/ ml were plated in 12 wells plate, and cell count was measured at
three time points 24, 48 and 72 hours. The error bars represent standard deviation of
three independent biological replicates for each cell line.
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3.3 - Reduction in Tumor Growth from Bptf KD 67NR Cells Is Dependent on
The Immune System.
Data from the previous experiments suggested a role of NURF in tumor
growth in vivo. One of the challenges that tumor cells must overcome in order to
progressively grow in vivo is avoiding the antitumor immune response.

The

effect of the host immune system on tumor growth have been supported by
number of observations, and the ability of the tumor cells to evade the immune
system is considered a hallmark of tumor cells (Hanahan & Weinnerg, 2011).
The observed deregulation of MHC-I and MHC-II genes in Bptf knockout in vitro
(Landry, et al., 2008) suggest that the immune system might be responsible for
the observed phenotype.

We anticipated that the observed reduction in tumor

growth might be due to active immune response against the tumor cells. Toward
this end, we investigated the effect of Bptf KD in tumorigenesis in
immunodeficient mouse model.

We chose NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ

mouse model. This model has two mutations in non-obese diabetic background
that lead to a complete absence of the adaptive and innate immune systems.
The first mutation is loss of function mutation in Prkdc gene, which is important
for functional T-cell and B-cell receptors; as a result it leads to eliminate the
adaptive immune cells. The second mutation is knockout for Il2 receptor gamma
gene, which encodes important subunit of the IL2 receptor, which plays a role in
lymphocytes and other immune cells maturation resulting in elimination of the
innate immune cells e.g. NK cells (DiSanto, et al., 1995). Using this model,
1X105 67NR cancer cells were injected into the mouse mammary fat pad. Three

35

weeks after injection, all mice developed tumors. The tumors were collected and
no significant difference in tumor weights was observed in both knockdowns
comparing to the control tumors (Figure 7).

This finding suggests that the

observed reduction in tumor growth in the BALB/c mice is due to immune
system.
Figure 7)
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Figure 7: NURF Does Not Affect Tumor Growth in NSG mice:
Tumor weights from mice injected with control, KD-1and KD-2 67NR breast cancer cell
lines. The error bars represent standard deviation for 5 mice per each group.

3.4- Normal Immune Cells Infiltration into the Tumor Tissues.
Results from the previous experiments suggested a role of the immune
system in the observed reduction in tumor growth. The cellular component of the
immune system plays important roles in mediating the antitumor response
36

against transformed cells. Studies in mice have shown the role of both the innate
and adaptive immune cells in mediating cytotoxic activity against malignant cells.
Mice lacking CTLs, T-helper or NK cells are more prone to develop induced
tumors compared to wild type mice (Dunn, et al., 2004). Another group of cells
that

infiltrates

into

the

tumor

tissues

is

MDSCs

which

have

an

immunosuppressive role against immune cells (Gabrilovich & Nagaraj, 2009).
We hypothesized that the reduction in tumor growth might be associated with
increase of CTLs, T-helper or NK cells or decrease of the MDSCs infiltration into
the tumor tissues.
In order to screen for the immune cells infiltration into the tumor tissue, we
used immuofluorescent technique to stain histological sections of tumors tissues.
We stained the tumor tissues derived from the BALB/c mice injected with 67NR
(Figure 8) and 66cl4 (Figure 9) cell lines using fluorochrome conjugated
antibodies for CD8, CD4, NK and CD11. The preliminary results from the 67NR
tumors showed slight increase of the CD8, CD4 and decrease in CD11b cells.
However, these results represent one tumor for KD-1 and two tumors for KD-2.
More tumors are required to determine the significance of this finding. (Figure 8
a-d). For the 66cl4 tumors no significant difference in CD8, CD4, NK and MDSC
cells infiltration were observed between the control and knockdown tumors
(Figure 9 a-d). Although, there is no significant difference in the immune cells
infiltration in the 66cl4 tumors, it could be possible that there is increase in the
activity and the efficiency of the effector immune cells in targeting the knockdown
tumors. (Rosenberg, 2001) (Zitvogel, et al., 2006).
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Figure 8)

Figure 8: Immune Cells Infiltration into Bptf KD 67NR Tumors:
Number of immune cells infiltrated into the 67NR primary tumors (control, KD-1 and KD2) developed in the mammary fat pad of BALB/c mice using immunofluorescence
staining. Antibodies were used for a) CD8a for CTL cells, b) CD4 for T-helper cells, c)
NKp46 for NK cells and d) CD11b for MDSCs. Counts were obtained as average cells
count from 10 fields relative to the control ((cell counts for KD / Cell count for control) X
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100). Only one tumor for KD-1 and 2 tumors for KD-2 are shown. Error bar in the KD-2
represent standard deviation for 2 tumors.

Figure 9)
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Figure 9: Normal Immune Cells Infiltration into Bptf KD 66cl4 Tumors:
Number of immune cells infiltrated into the 66cl4 primary tumors (control, KD-1 and KD-2)
developed in the mammary fat pad of BALB/c mice using immunofluorescence staining.
Antibodies were used for a) CD8a for CTL cells, b) CD4 for T-helper cells, c) NKp46 for NK
cells and d) CD11b for MDSCs. Counts were obtained as average cells count from 10 fields
relative to the control ((cell counts for KD / Cell count for control) X 100). Error bars represent
standard deviation for 3 biological replicates for each group.

3.5- Microarray Data Show Overexpression of Genes Involved in Immune
Response.
The significant reduction in tumors weight from the two different cell lines (67NR
and 66cl4) in BALB/c mice after reducing NURF function suggested a role for NURF in
regulating genes that has a role in tumor survival in vivo. In order to identify NURF
dependent genes we measured gene expression profile of tumor tissues obtained from
the BALB/c mice injected with the 67NR and 66cl4 breast cancer cell lines (Figure 10).
Microarray analyses were performed in collaboration with Dr. Catherin Dumur at Virginia
Commonwealth University. Tumor tissues were subjected to gross histological
examination using hematoxylin and eosin (H&E) stain to determine the percentage of
tumor cells. The tumor content of the tissues used for the arrays was 70% to 100% and
necrotic tissues, if present, were removed by macrodissection.

The following

microarray data are preliminary; the 67NR data represent two tumors for the KD-2 and
three tumors for the control, and the 66cl4 data represent two tumors for the KD-1, KD-2
and control. More tumors will be used to complete three biological replicates for the
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control, KD-1 and KD-2. Unsupervised hierarchical cluster analyses based on 22,960
probe sets showed clustering for KD and control samples (Figure 10 a, c data
obtained from Dr. Dumur). There were 88 probe sets in the 67NR tumors and 105
probe sets in 66cl4 tumors that showed significant deregulation between the control and
KD (p-value < 0.01, False Discovery Rate FDR < 15%) (Figure 10 b, d data obtained
from Dr. Dumur).

A gene ontology analysis using the database for annotation,

visualization and integrated discovery (DAVID) (Huang, et al., 2009) showed that the
highest enrichment terms are associated with immune response in both cell lines 67NR
(Table2) 66cl4 (Table 3). Genes from 67NR tumors include genes involved in antigen
presentation on MHC-I molecules (TAP2 and Tapbp), MHC-I genes (H2-D1and H2-L)
and MHC-II gene (H2-DMa) (Table 4). As the tumor tissues that were used for the
microarray experiments might be infiltrated with immune cells, identifying Bptf
dependent genes will need to be confirmed in cells grown in vitro. In the preliminary
results of gene expression in vitro, we didn’t observe overexpression of these genes in
the two KD cell lines, which suggests that the observed overexpression of these genes
in the array is due to active immune cells infiltrated into the tumor site (Figure 11 a).
Indeed, enrichment of lymphocyte-associated genes among the overexpressed probes
was observed (Table2).

We detected down regulation of cyclin D1 isoform Ccnd1b

gene which is also down regulated in Bptf KO ESCs and MEFs (Dr. Landry unpublished
data).
Genes from 66cl4 tumors include genes involved in antigens presentation on
MHC-I (Psmb8, Psmb9 and Tapbpl), MHC-I gene (H2-K1), MHC-II gene (H2-DMb2)
and chemokine genes (Cxcl16, Cxcl9 and Xcl1) (Table 5). We anticipated that the
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enrichments of these genes is more likely due to active immune cells infiltrated into the
tumor site, as the preliminary results of gene expression in vitro did not show
overexpression of these genes except Cxcl16 (Figure 11 b).

This suggestion is

supported by the enrichment of T-lymphocyte genes in the overexpressed genes from
66cl4 tumors (Table 3).

Cxcl16, which is also overexpressed in the cell culture, is a

chemokine that recognized by chemokine receptor Cxcr6, which is expressed on the
surface of immune cells e.g. CD8+, CD4+ and NK lymphocytes (Deng, et al., 2010).
One of the Cxcl16 roles is inducing chemotactic migration for cells that express Cxcr6.
Although more tumors are going to be subjected to the microarray and qRTPCR, the current data suggested that the immune system is involved in the phenotype
observed in BALB/c mice. Complete microarray and in vitro gene expression data will
be required to identify the potential Bptf-dependent candidate genes.

Figure 10)
a)
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b)

c)
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d)

Figure 10: Microarray Analysis for 67NR and 66cl4 Tumors:
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a) Unsupervised cluster analysis based on 22,960 probe sets for 67NR tumors using euclidean
distance and average linkage. Three control tumors and two KD-2 (short hairpin #5) tumors
were used.
b) Supervised cluster analysis for 67NR tumors based on 88 significant (p-value < 0.01, False
discovery date FDR < 12%) probe sets that showed > 2 fold change between the control and
KD. Three control tumors and two KD-2 (short hairpin#5) tumors were used C) Unsupervised
cluster analyses based on 22,960 probe sets using centered correlation and average linkage for
66cl4 tumors. Two tumors for the control, KD-1 (short hairpin #3) and KD-2 (short hairpin #5)
were used.
d) Supervised cluster analysis for 66cl4 tumors based on 105 significant (p-value < 0.01, False
discovery date FDR < 12%) probe sets that showed > 2 fold change between the control and
KD. probe sets using centered correlation and average linkage for 66CL4 tumors. Two tumors
for the control, KD-1 (short hairpin #3) and KD-2 (short hairpin #5) were used.

Table 2)

Table 2: Enrichments of Terms with Immune Response Function in 67NR Tumors:
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Gene ontology analysis using DAVID functional annotation chart tools that identify enriched
annotation terms in a gene list. Genes list from 67NR tumors for genes that were
overexpressed with 2 or more fold changes show the highest significant enrichments terms are
associated with immune response.

Table 3)

Table 3: Enrichments of Terms with Immune Response Function in 66cl4 Tumors:
Gene ontology analysis using DAVID functional annotation chart tools that identify enriched
annotation terms in a gene list. Genes list from 66cl4 tumors for genes that were
overexpressed with 2 or more fold changes show the highest significant enrichments terms are
associated with immune response.

Table 4)
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Gene Title

Fold
p-value q-value
Gene
Change
(a-level: (FDR≤12
Symbol (Geometr
0.01)
%)
ic)

1 transporter 2, ATP-binding cassette

Tap2

4.89

2.73E-03 1.18E-01

2 histocompatibility 2, class II, locus DMa

H2-DMa

4.12

1.60E-03 1.12E-01

3 TAP binding protein

Tapbp

3.27

3.07E-04 1.12E-01

4 histocompatibility 2, D region locus 1

H2-D1

2.09

1.79E-03 1.12E-01

5 histocompatibility 2, D region

H2-L

2.07

6.79E-04 1.12E-01

Table 4: Genes from 67NR tumors:
Candidate genes from 67NR tumors that show significant change compared to control tumors
(p-value α-level0.001 FDR < 12%).

Table 5)
Gene
Symbol

Gene Title

Fold
p-value q-value
Change
(a-level: (FDR≤15
(Geometr
0.01)
%)
ic)

1

proteasome (prosome, macropain) subunit, beta type 9

Psmb9

2.4

1.21E-04 1.21E-01

2

TAP binding protein-like

Tapbpl

1.8

7.32E-03 1.47E-01

3

histocompatibility 2, class II, locus Mb2

H2-DMb2

1.6

4.74E-03 1.47E-01

4

chemokine (C-X-C motif) ligand 16

Cxcl16

2.4

3.38E-03 1.47E-01

5

chemokine (C-X-C motif) ligand 9

Cxcl9

5.1

6.75E-03 1.47E-01

7

proteasome (prosome, macropain) subunit, beta type 8

Psmb8

2.4

2.38E-03 1.47E-01

8

histocompatibility 2, K1, K region

H2-K1

1.7

6.84E-03 1.47E-01

9

chemokine (C motif) ligand 1

Xcl1

2.4

1.95E-03 1.47E-01

Table 5: Genes from 66cl4 tumors:
Candidate genes from 66cl4 tumors that show significant change comparing to control tumors
(p-value α-level0.001 FDR < 15%)

Figure 11)
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Figure 11: Q RT-PCR for 67NR and 66cl4 Breast Cancer Cell Lines:
a) Differential gene expression of Tapbp, H2-Mb2, Tap1, Tap2, H2-D1, H2-Dma, Ccnd1a,
Ccnd1b and Bptf were analyzed in the 67NR breast cancer cell lines using qRT-PCR. βactin was used as a housekeeping gene for normalization. Error bars represent standard
deviation of two biological replicates.
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b) Differential gene expression of Cxcl16, H2-Mb2, Psmb8, Psmb9, H2-D1, H2-K1, Cxcl9,
Ccnd1a, Ccnd1b and Bptf were analyzed in the 666cl4 breast cancer cell lines using
qRT-PCR. β-actin was used as a housekeeping gene for normalization. Error bars
represent two biological replicates for Cxcl16, Psmb8, Psmb9, H2-D1, H2-K1, Ccnd1a
and Bptf.
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4- Discussion and Future Directions

4.1- Discussion.
Epigenetic alterations are important factors in tumorigenesis (Jones & Baylin,
2002). The reversible nature of epigenetic changes makes these types of aberrant
alterations potential targets for cancer therapy. Extensive research in understanding
DNA methylation and histone modifications provide broad understanding of these
mechanisms, which led develop drug therapies targeting these mechanisms (Sharma,
et al., 2010). Chromatin remodeling complexes are epigenetic regulators that affect
gene expression by changing the chromatin structure (Clapier & Cairns, 2009). NURF
is an ATP-chromatin remodeling complex that is essential for normal embryonic
development through regulating important developmental pathways (Landry, et al.,
2008). ESCs lacking NURF through KO of its unique subunit Bptf were unable to form
teratomas in NOD/SCID mice (Landry, et al., 2008). Moreover, Bptf KO in ESCs, MEFs
and DP thymocytes showed deregulation of genes involved in tumor progression e.g.
MHC-I molecules and E- and N- cadherin genes (Landry, et al., 2008) (Landry, et al.,
2011).

These findings suggested that NURF might have an impact on tumor growth.

Prior to this work, the role of mammalian NURF in tumorigenesis was unknown.
The subject of the current work is to study the role of NURF in tumorigenesis in
vivo. We hypothesized that eliminating NURF function might reduce tumor growth in
vivo. Our findings suggest that abolishing NURF function in tumor cells reduces the
tumor growth in the presence of intact immune system.
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We used a syngeneic breast cancer mouse model to study the impact of eliminating
NURF on tumor growth. Using shRNA technology we generated two stable KD breast
cancer cell lines with two different shRNA targeting NURF essential subunit Bptf. In
order to investigate the impact of eliminating NURF in the tumor growth in vivo, we
injected the Bptf KD breast cancer cell lines into the mammary fat pad of BALB/c mice.
After three weeks of injection of the 67NR cells, we found significant reduction in tumor
growth in mice injected with KD cell lines comparing to mice injected with control cells.
While 12 out of 13 mice injected with the control cells formed tumors, only 3 out of 13
and 6 out 16 mice injected with KD-1 and KD-2 cells, respectively, developed tumors. A
similar reduction in tumor size but not frequency was observed with the 66cl4 breast
cancer cells (work done by S. Alkhatib data not shown).

Reduction in primary tumor

growth in BALB/c derived 4T1 breast cancer mouse model have been observed in
number of study that target genes involved in tumor survival (Nasrazadani & Lynn Van
Den Berg, 2011) (Hong, et al., 2009) .

One study showed significant reduction in

mammary tumor growth in mice injected with 4T1breast cancer cells stably express
shRNA targeting IL-17 receptor (Nam, et al., 2008).

These tumor cells were less

response to IL-17 that is secreted by immune cells such as CD8+ T-cells which acts as
survival signal for tumor cells.

Next, it was important to determine if the observed reduction in tumor growth is
due to a change in growth capacity in vitro following Bptf KD.

By measuring the

population doubling time for the breast cancer cell lines in vitro, we found that KD of
Bptf does not affect the growth capacity of the tumor cells. The obtained population
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doubling time in our experiment is similar to previously published results (Eckhardt, et
al., 2005). This suggests that the observed reduction in tumor growth is due to an effect
that the tumor cells encounter in vivo.
One important step during tumor growth is the ability of the transformed cells to
avoid the antitumor response mediated by the host immune system (Dunn, et al., 2004)
(Hanahan & Weinnerg, 2011).

As previously observed in vitro that Bptf deregulates

MHC-I and MHC-II genes (Landry, et al., 2008), which are important for proper immune
response. Deregulation of MHC-I and MHC-II genes are observed in number of tumors
such as breast cancer, prostate cancer and melanoma (Campoli & Ferrone, 2008). We
hypothesized that the immune system might preferentially target the Bptf KD tumors
cells. To test this, we used NSG mouse model which has loss of functional innate and
adaptive immune system. Bptf KD-1, KD-2 and control 67NR breast cancer cell lines
were injected into the mammary fat pad of these mice with the same number of cells
that were injected in the BALB/c mice. After three weeks of injection, all the mice
injected with the KD-1, KD-2 and control cells developed tumors. The obtained tumor
weights showed no significance difference between the KDs and control tumors.
Similar finding was obtained using the 66cl4 cells (work done by S. Alkhatib data not
shown).
Our finding that showed reduction in tumor growth in BALB/c mice but not in
immunodeficient mice in agreement with previously published results that showed a
significant reduction in primary tumor growth in BALB/c mice but not in immunodeficient
mice after injection with 4T1 breast cancer cells lacking indolamine 2,3-dioxgenase that
promote immune escape capability of the transformed cells.
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In this study, KD of

indolamine 2,3-dioxgenase (IDO1) which is an enzyme responsible for tryptophan
catabolism in 4T1 cells showed reduction in tumor growth after injection of these cells
into the syngeneic BALB/c mice but not in mice lacking functional immune system
(Levina, et al., 2012). Over expression of IDO1 in tumor microenvironment is known to
promote tumor cells to escape the antitumor immune response likely by inhibiting Tcells activity (Prendergast, 2008). This suggests a similar role of NURF in transformed
cells, in which Bptf KD in tumor cells; promote active antitumor immune response
against these cells.
The antitumor response of the immune system is mediated mainly through the
cellular components of the innate and the adaptive immune system like NK, CTLs and
T-helper cells. While the antitumor role and the favorable outcome are associated with
lymphocytes infiltration into the tumor microenvironment (Naito, et al., 1998), MDSCs
are known to oppose the immune response and act as immunosuppressive cells
(Gabrilovich & Nagaraj, 2009). We screened for CTLs, T-helper, NK and MDSCs cells
infiltration into the tumor tissues isolated form the BALB/c mice injected with 67NR and
66cl4 breast cancer cell lines using immunofluorescence staining with antibodies for
CD8a (CTLs), CD4 (T-helper cells), NKp46 (NK cells) and CD11b (MDSCs). As not all
the mice injected with the 67NR KD cells form tumors, we only subjected one tumor for
KD-1 and two tumors for KD-2 for the staining. We observed a relative increase in
CD8a and CD4 and decrease in CD11b from KD-2 tumors. However, more tumors
need to be used in order to confirm the significance of any observed findings. From
mice injected with the 66cl4 cells, we did not observe a significant difference between
the control and KD tumors in the CD8a, CD4, NKp46 and CD11b cells. Although no
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significant increase in the immune cells infiltration into KD tumor microenvironments,
there might be an increase in the cells efficiency or activity in or decrease in regulatory
cells that have immunosuppressive role, which can’t be distinguish by using single
antibody for each cell type (Rosenberg, 2001) (Zitvogel, et al., 2006).

In order to

differentiate between the effector T-cells and regulatory T-cell populations infiltrated into
the tumor sites, fluorescence activated cell sorting (FACS) analysis needs to be
performed using specific markers for each cell type such as Fox3+ that distinguish
regulatory T-cells from effector T-cells (Bui, et al., 2006).
To identify NURF dependent genes in tumor cells, we subjected the tumor
tissues isolated from BALB/c mice to microarray analysis.

From our preliminary

microarray data we observed enrichment of genes involved in immune response
pathways.

Among the overexpressed genes from the 66cl4 KD tumors, there is

enrichment of lymphocyte-associated genes, which indicates infiltration of active
immune cells into the KD tumors. The observed overexpression of MHC-I, MHC-II and
APM (Psmb7and Psmb8) genes in the array is more likely due to immune cells
infiltration since the qRT-PCR experiment showed down regulation of these genes in
the tumor cells in vitro. Another group of genes that is overexpressed in 66cl4 tumors
is a set of chemokines (Cxcl16, Xcl1 and Cxcl9) which induce the migration of the
immune cells. Cxcl16 is of particular interest since it is also overexpressed in 66cl4 cell
lines in vitro, and it has a role in immune cells infiltration (Hojo, et al., 2007).

A

colorectal cancer study showed an association between Cxcl16 expression in tumor
cells and CD4+ and CD8+ T-lymphocyte infiltration (Hojo, et al., 2007). In this study it
has been shown that overexpression of Cxcl16 also associated with favorable
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prognosis. Xcl1 is another chemokine that induce infiltration of CD8+ dendritic cells in
mouse and CD141+dendritic cells in human which are specialized in antigen
presentation to CTLs and augment CTL cytotoxic activity (Lei & Takahama, 2012). A
study in human breast cancer cell lines showed overexpression of XCL1 following
treatment with DNA methylation and histone acetylation inhibitors (Keen, et al., 2004).
In order to confirm whether Xcl1 expression is Bptf dependent, the expression will be
tested using 66cl4 cell lines grown in vitro. Cxcl9 is a chemokine that induce attraction
for immune cells, and it has antitumor immune response (Walser, et al., 2007). The
preliminary result from in vitro gene expression for one replicate showed down
regulation of Cxcl9. More samples need to be tested to confirm whether Cxcl9 is Bptfdependent or not.
Data from the 67NR only represent 2 tumors for the KD-2 and 3 tumors for the
control. We also, observed enrichment of genes involved in the immune response in the
KD tumors. The observed overexpression of MHC-I (H2-D1), MHC-II (H2-Dma) and
APM (Tapbp and TAP2) in the microarray but not in cells growing in vitro more likely
was due to immune cells infiltration.

We detected down regulation of cyclin D1 b

isoform in vitro. This in agreement with a previous finding that showed cyclin D1 down
regulation in Bptf KO ESCs, MEFs (Dr. Landry unpublished data).

Along with its

classical role as a cell cycle regulator, cyclin D1 plays a role as a regulator of gene
transcription through its interaction with transcription factors as well as HATs and
HDACs coactivators (Velasco-Velazquez, et al., 2011). We did not observe a reduction
in cell growth in vitro and tumor growth in NSG mice, which indicates that reduction of
cyclin D1 does not affect the cellular proliferation in Bptf KD cells. Knockout of cyclinD1
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promote MEF differentiation to adipocyte, which indicates that cyclinD1 involved
regulation of genes control this differentiation (Fu, et al., 2005). Down regulation of
cyclin D1 in the 67NR might altered expression of genes that enhance the tumor cell
immunogenicity e.g. overexpression of genes that might serve as tumor associated
antigens and enhance the tumor cell recognition by the immune cells. Currently we
don’t have complete data from KD-1 and KD-2 67NR tumors. We expect that more
tumors will help in identifying set of genes, such as chemokines, that might account for
the observed phenotype.
The microarray experiment is currently ongoing and we anticipate that complete
microarray and qRT-PCR data will provide us with a better set of potential NURFdependent candidate genes that account for the observed phenotype in tumor growth.
In conclusion, our findings that KD Bptf reduces tumor growth in vivo with an
intact immune system, but not in vitro, and that reduction is retained in immunedepleted
mice support our hypothesis that eliminating NURF function in tumor cells reduces the
tumor growth in vivo likely through an increased active antitumor immune response. At
present time we don’t have complete data from the microarray and qRTpPCR to identify
the Bptf dependent genes that account for the observed phenotype. However,
enrichment of genes associated with immune response supports the role of the immune
system in the observed phenotype.

4.2- Future Directions.
The ultimate goal for studying roles of NURF in tumorigenesis is to provide
complete understanding of how NURF might be involved in tumor growth.
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Four

questions need to be addressed in order to achieve this goal. First, what component of
the immune system is active against tumor cells lacking Bptf? Second, what are the
NURF dependent genes that underlie the observed phenotype? Third, is the observed
phenotype specific for the breast cancer models or similar finding can be obtained in
other solid tumor models?

Fourth, does the observed phenotype also occur in

humans?.
As the data suggests that eliminating NURF in tumor cells promotes the
antitumor immune response, it is important to determine what component of the immune
system is involved. The two important main cells that mediate the tumor cytotoxicity are
NK and CTL cells (Russell & Ley, 2002). To answer this question investigation of the
NK and CTL activity against Bptf KD tumor cells in vitro will be performed. Next, the in
vitro study will be followed by in vivo study using animal model lacking the immune
effector cell population either by genetic modification or antibody treatment.
Complete data from the microarray will provide a set of candidate genes that are
NURF dependent. Molecular analysis will be performed to identify the role of NURF in
regulating

these

genes.

DNase

I-hypersensitivity

analysis

and

chromatin

immuneprecipitation (ChIP) assay will help to determine whether NURF directly
regulates these genes.
It is important to determine whether the role of NURF in tumor growth is not
limited to the breast cancer model that is used in this work. Towered this end, studying
the effect of NURF in other solid tumor models e.g. melanoma, will be essential.
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Finally, many promising gene targets using mouse models don’t translate to
human therapies. It is important to know if NURF dependent pathways and genes
identify in the mouse model also apply to human.
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